EXEL · Exelixis Inc
Snapshot
50 fields · last close| Market Cap | $14.75B |
| P/E | 17.09 |
| Float | 246.6M |
| Beta | 0.44 |
| Volatility | 11.1% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 79.1 |
| Price | 60.73 |
| Change | +2.05% |
| Prev Close | 59.51 |
| Open | 60.00 |
| Day Low | 58.59 |
| Day High | 60.00 |
| Avg Vol | 2 |
| Avg $ Vol | $143.5M |
| 52W High | 61.66 |
| 52W Low | 33.76 |
| 52W Pos | 96.7% |
| From High | −1.51% |
| From Low | +79.89% |
| Max DD 1Y | — |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | — |
| SMA 50 | — |
| SMA 200 | — |
| RSI (14) | — |
| Vol 30D | — |
| Vol 90D | — |
| 1Y Range | 34–62 |
| Daily bars | — |
| Perf Week | — |
| Perf Month | — |
| Perf Quarter | — |
| Perf Half Y | — |
| Perf Year | — |
| Perf YTD | — |
| Prev Day | +2.05% |
| Clavix | B+ |
| Debt / Eq | 0.00 |
| Curr Ratio | 3.56 |
| Int Cover | 5.1× |
| FCF Margin | 37.8% |
| Rev Growth | +7.0% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 5 / 35 |
Clavix risk grade
regraded every trading dayEXEL grades B+, 79.1 of 100. Steadiest on Macro Resilience (68), most exposed on News Sentiment (59, mixed). 3 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 5 of 35 in Biotechnology by Clavix score.
How rough the ride is
| EXEL | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.44 | 0.50 |
| Volatilityannualized | 11.1% | 14.4% |
| Max drawdown, past yearworst peak-to-trough fall | — | — |
| Typical daily movemedian absolute daily change | — | — |
| Days beyond ±3%of the last 0 sessions | — | — |
Market sensitivity
| EXEL | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.44 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| EXEL | |
|---|---|
| 1 week | — |
| 1 month | — |
| Year to date | — |
| 1 year | — |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| EXEL | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 31 Aug |
| Average score0 most bearish, 100 most bullish | 53 |
| Bullish · bearisharticles above 60 · below 40 | 15 · 10 |
| Directionarticles whose tone is improving vs worsening | 15 ↑ 10 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| EXEL | |
|---|---|
| Revenue growthyear over year | +7.0% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openZacks Research raised its FY2028 earnings estimate for Exelixis to $4.22 per share in a research note issued on Thursday, October 8th. The article body is truncated, so no further details are available.
Exelixis stock returned 46% over the past twelve months, compared with 17.8% for the S&P 500. The company has been buying back its own shares, cutting its total share count by 21% over the last three years.
A federal appeals court ruled in Exelixis's favor against MSN Laboratories, affirming that even though MSN had its own patent on a specific crystal form of cabozantinib (L)-malate (called Form S), it still infringes Exelixis's earlier, broader patents covering crystalline forms of that compound. MSN had argued the broader Exelixis patents were invalid for failing the written-description requirement, and the court rejected that argument.
Exelixis is facing a three-month delay in the FDA review of zanzalintinib, pushing the potential decision date for its colorectal cancer use to March 2027.
Exelixis is facing a three-month delay in the FDA review of its drug zanzalintinib, pushing a potential decision for use against colorectal cancer (CRC) to March 2027.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| ASND | Ascendis Pharma A/S | B+ | $13.92B | 17.07 | 0.38 | Compare |
| NBIX | Neurocrine Biosciences Inc | B+ | $13.74B | 19.74 | 0.33 | Compare |
| HALO | Halozyme Therapeutics Inc | B | $12.44B | 30.52 | 0.94 | Compare |
| BBIO | BridgeBio Pharma Inc | B | $12.37B | — | 0.95 | Compare |
| MDGL | Madrigal Pharmaceuticals Inc | B | $10.45B | — | -1.10 | Compare |
| INSM | Insmed Inc | C | $21.14B | — | 0.80 | Compare |
| TWST | Twist Bioscience Corp | D+ | $9.96B | — | 2.15 | Compare |
| INCY | Incyte Corp | B+ | $22.02B | 13.65 | 0.78 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.